Combination of ETV, TQ-A3334 and TQ-B2450 for CHB (Neptune Study)
Status:
Not yet recruiting
Trial end date:
2021-06-30
Target enrollment:
Participant gender:
Summary
This study is a single-center, randomized, prospective, open-label Phase 2 Clinical trial to
evaluate efficacy and safety of ETV and TQ-A3334 combinated with/without inhibitor of
TQ-B2450 versus ETV alone in chronic hepatitis B patients. Patients were randomized to one of
3 different antiviral treatment.